McEwen Mining's stock has dropped 19% since September, but the market is overly focused on upcoming November results and the Gold Bar project recovery. The analyst values Gold Bar at about $3 per share and sees significant upside from the Los Azules copper project, which contributes $13 of the $31 risked value per share. The current share price is supported by gold mines and the Grey Fox project, with copper assets nearly free. The recommendation is to buy McEwen shares with a price target of $23.72, offering a real annual return of about 15%. A half position is advised until financing details are clear.
McEwen Mining's recent stock discussion provides context for Basic Materials sector activity on Pluang. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 21, 2026 00:51 WIB: Of 83 priced US stocks, 52 rose and 31 fell. Notable movers include HYMC at USD 17.53 with a 1-day change of +3.97%, SVM at USD 9.40 down -3.79% with 100% buy order activity, and SOLS at USD 62.43 up +3.24%, with typical hold times ranging from 2 to 5 days.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
